For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Dr. Konstantinos Tzelepis' research is focused on uncovering epigenetic mechanisms that implicated in devastating malignancies, such as acute myeloid leukaemia (AML). His group is part of the Centre for Pathway Analysis at the Milner Therapeutics Institute (University of Cambridge, UK). Kostas completed his Ph.D. at the Wellcome Sanger Institute, where he pioneered the use of CRISPR-Cas9 technology to perform the first disease-focused genome-wide recessive screen in AML. He was awarded the Sir Henry Wellcome Fellowship to investigate the role of RNA modifications and splicing in cancer initiation and maintenance. His efforts have led to the identification of several novel RNA-binding/modifying proteins essential for AML cell survival. His ultimate aim is the development of new effective treatments against aggressive cancers, via close collaborations with academia and industry, including the Kouzarides lab (Wellcome-CRUK Gurdon Institute) and Storm Therapeutics (UK).
Have questions about this webinar? Contact us at: email@example.com